Related Videos
Video
Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor
Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.
Video
Research Update for Triple Negative MBC | 2021-2022 EMBRACE MBC Virtual Forum Series
Antonio Giordano, MD, PhD; Sarah Sammons, MD; and Morgan Rutter, MS, BSN, RN, discuss advances in research and treatment for patients with triple negative metastatic breast cancer.